Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | MAPKAPK2 | P49137 | 3/20 | 0.34 |
| ▸ | ABL1 | P00519 | 3/20 | 0.33 |
| ▸ | EGFR | P00533 | 2/20 | 0.33 |
| ▸ | BRAF | P15056 | 2/20 | 0.33 |
| ▸ | BCR | P11274 | 2/20 | 0.33 |
| ▸ | SRC | P12931 | 1/20 | 0.33 |
| ▸ | PRKACA | P17612 | 1/20 | 0.33 |
| ▸ | PRKACG | P22612 | 1/20 | 0.33 |
| ▸ | PRKACB | P22694 | 1/20 | 0.33 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.32 |
| ▸ | BUB1 | O43683 | 2/20 | 0.32 |
| ▸ | XDH | P47989 | 1/20 | 0.32 |
| ▸ | CDK1 | P06493 | 1/20 | 0.31 |
| ▸ | PRKCA | P17252 | 1/20 | 0.31 |
| ▸ | PLK1 | P53350 | 1/20 | 0.31 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.31 |
| ▸ | CDK9 | P50750 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7916081 | 0.79 | CNR1 (0.47) | MAPKAPK2ABL1BCRPRKCAPLK1 | |
| SCHEMBL7913085 | 0.77 | VCP (0.46) | MEN1POLBKMT2AMAPKAPK2PLK1 | |
| SCHEMBL7905830 | 0.76 | SIRT2 (0.48) | MEN1POLBKMT2APLK1GSK3B | |
| SCHEMBL6799593 | 0.74 | CA12 (0.42) | ABL1EGFRBRAFBCRSRC | |
| SCHEMBL7913081 | 0.74 | HDAC3 (0.46) | MEN1POLBKMT2AMAPKAPK2ABL1 | |
| SCHEMBL12852522 | 0.73 | NTRK1 (0.45) | MEN1KMT2AEGFRPLK1CDK9 | |
| SCHEMBL7915476 | 0.73 | CNR1 (0.45) | MEN1POLBKMT2AABL1EGFR | |
| SCHEMBL7905484 | 0.72 | MEN1 (0.50) | MEN1KMT2AABL1EGFRBCR | |
| SCHEMBL7905810 | 0.72 | HPGDS (0.38) | MEN1POLBKMT2AMAPKAPK2ABL1 | |
| SCHEMBL8230052 | 0.71 | ADORA2A (0.53) | MEN1POLBKMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110136796-A1 | IDO Inhibitors | NEWLINK GENETICS (US) | 2011-06-09 | — | — | US | claimed |
| EP-2291187-A2 | IDO INHIBITORS | Newlink Genetics (US) | 2011-03-09 | — | — | EP | claimed |
| WO-2009132238-A2 | IDO INHIBITORS | NEWLINK GENETICS (US) | 2009-10-29 | — | — | WO | claimed |
| US-6211220-B1 | ANTITUMOR AGENTS AND ANTICARCIINOGENIC AGENTS | CELL PATHWAYS, INC. | 2001-04-03 | — | — | US | claimed |
| US-9174942-B2 | IDO inhibitors | NEWLINK GENETICS CORPORATION (US) | 2015-11-03 | — | — | US | disclosed |
| US-20140323740-A1 | IDO Inhibitors | NEWLINK GENETICS CORPORATION (US) | 2014-10-30 | — | — | US | disclosed |
| US-8748469-B2 | IDO inhibitors | NEWLINK GENETICS CORPORATION (US) | 2014-06-10 | — | — | US | disclosed |
| US-20110136796-A1 | IDO Inhibitors | NEWLINK GENETICS (US) | 2011-06-09 | — | — | US | disclosed |
| EP-2291187-A2 | IDO INHIBITORS | Newlink Genetics (US) | 2011-03-09 | — | — | EP | disclosed |
| WO-2009132238-A2 | IDO INHIBITORS | NEWLINK GENETICS (US) | 2009-10-29 | — | — | WO | disclosed |
| US-6211220-B1 | ANTITUMOR AGENTS AND ANTICARCIINOGENIC AGENTS | CELL PATHWAYS, INC. | 2001-04-03 | — | — | US | disclosed |
| WO-1994029277-A1 | AMILINO- OR PYRIDYLAMINO- CYCLOBUTENE- 1,2-DIONE DERIVATIVES AS cGMP PHOSPHODIESTERASE INHIBITORS | SMITHKLINE BEECHAM PLC (GB) | 1994-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140323740-A1 | IDO Inhibitors | IDO1, IDO2, INMT | MEN1 2262/4885POLB 2996/4885KMT2A 520/4885 |
| US-20110136796-A1 | IDO Inhibitors | IDO1, IDO2, INMT | MEN1 2262/4885POLB 2996/4885KMT2A 520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.